Literature DB >> 28073956

The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.

Lillian J Barra1, Janet E Pope1, Carol Hitchon2, Gilles Boire3, Orit Schieir4, Daming Lin5, Carter J Thorne6, Diane Tin6, Edward C Keystone5, Boulos Haraoui7, Shahin Jamal8, Vivian P Bykerk5,9.   

Abstract

Objective: . RA is associated with an increased risk of cardiovascular events (CVEs). The objective was to estimate independent effects of RA autoantibodies on the incident CVEs in patients with early RA.
Methods: Patients were enrolled in the Canadian Early Inflammatory Arthritis Cohort, a prospective multicentre inception cohort. Incident CVEs, including acute coronary syndromes and cerebrovascular events, were self-reported by the patient and partially validated by medical chart review. Seropositive status was defined as either RF or ACPA positive. Multivariable Cox proportional hazards survival analysis was used to estimate the effects of seropositive status on incident CVEs, controlling for RA clinical variables and traditional cardiovascular risk factors.
Results: . A total of 2626 patients were included: the mean symptom duration at diagnosis was 6.3 months ( s . d . 4.6), the mean age was 53 years ( s . d . 15), 72% were female and 86% met classification criteria for RA. Forty-six incident CVEs occurred over 6483 person-years [incidence rate 7.1/1000 person-years (95% confidence interval 5.3, 9.4)]. The CVE rate did not differ in seropositive vs seronegative subjects and seropositivity was not associated with incident CVEs in multivariable Cox regression models. Baseline covariates independently associated with incident CVEs were older age, a history of hypertension and a longer duration of RA symptoms prior to diagnosis.
Conclusion: The rate of CVEs early in the course of inflammatory arthritis was low; however, delays in the diagnosis of arthritis increased the rate of CVEs. Hypertension was the strongest independent risk factor for CVEs. Results support early aggressive management of RA disease activity and co-morbidities to prevent severe complications.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  ACPA; RF; cardiovascular disease; complications; rheumatoid arthritis; seropositive

Mesh:

Substances:

Year:  2017        PMID: 28073956     DOI: 10.1093/rheumatology/kew474

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

1.  Abdominal Obesity in Comparison with General Obesity and Risk of Developing Rheumatoid Arthritis in Women.

Authors:  Nathalie E Marchand; Jeffrey A Sparks; Sara K Tedeschi; Susan Malspeis; Karen H Costenbader; Elizabeth W Karlson; Bing Lu
Journal:  J Rheumatol       Date:  2020-07-15       Impact factor: 4.666

2.  Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

Authors:  Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2017-04-01       Impact factor: 4.666

Review 3.  Hypertension in connective tissue disease.

Authors:  Qiang Luo; Yiwen Zhang; Xiaoqian Yang; Li Qin; Han Wang
Journal:  J Hum Hypertens       Date:  2022-05-03       Impact factor: 3.012

4.  Screening for preclinical parenchymal lung disease in rheumatoid arthritis.

Authors:  Anthony J Esposito; Jeffrey A Sparks; Ritu R Gill; Hiroto Hatabu; Eric J Schmidlin; Partha V Hota; Sergio Poli; Elaine A Fletcher; Wesley Xiong; Michelle L Frits; Christine K Iannaccone; Maria Prado; Alessandra Zaccardelli; Allison Marshall; Paul F Dellaripa; Michael E Weinblatt; Nancy A Shadick; Ivan O Rosas; Tracy J Doyle
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

5.  13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.

Authors:  Mary E Walker; Patricia R Souza; Romain A Colas; Jesmond Dalli
Journal:  FASEB J       Date:  2017-05-02       Impact factor: 5.191

6.  Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders.

Authors:  Alex Dregan; Phil Chowienczyk; Mariam Molokhia
Journal:  Heart       Date:  2017-06-10       Impact factor: 5.994

Review 7.  Mechanisms of hypertension in autoimmune rheumatic diseases.

Authors:  Erin B Taylor; Victoria L Wolf; Elena Dent; Michael J Ryan
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

8.  Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.

Authors:  Piero Ruscitti; Paola Cipriani; Vasiliki Liakouli; Daniela Iacono; Ilenia Pantano; Domenico Paolo Emanuele Margiotta; Luca Navarini; Giulia Maria Destro Castaniti; Nicola Maruotti; Gerardo Di Scala; Licia Picciariello; Francesco Caso; Sara Bongiovanni; Rosa Daniela Grembiale; Fabiola Atzeni; Raffaele Scarpa; Federico Perosa; Giacomo Emmi; Francesco Paolo Cantatore; Giuliana Guggino; Antonella Afeltra; Francesco Ciccia; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2019-09-03       Impact factor: 5.156

9.  Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study.

Authors:  Gian Luca Erre; Matteo Piga; Anna Laura Fedele; Silvia Mura; Alessandra Piras; Maria Luisa Cadoni; Ignazio Cangemi; Martina Dessi; Gabriele Di Sante; Barbara Tolusso; Elisa Gremese; Alberto Cauli; Arduino Aleksander Mangoni; Pier Sergio Saba; Ciriaco Carru; Gianfranco Ferraccioli; Alessandro Mathieu; Giuseppe Passiu
Journal:  Mediators Inflamm       Date:  2018-02-01       Impact factor: 4.711

Review 10.  Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies.

Authors:  Mir Sohail Fazeli; Vadim Khaychuk; Keith Wittstock; Boris Breznen; Grace Crocket; Mir-Masoud Pourrahmat; Leticia Ferri
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.